

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 8, 2026

Neuroendocrine Tumors Biobank

RRID:SCR_004380

Type: Tool

Proper Citation

Neuroendocrine Tumors Biobank (RRID:SCR_004380)

Resource Information

URL: <http://www.ucl.ac.uk/cancer/medical-genomics/clinepi>

Proper Citation: Neuroendocrine Tumors Biobank (RRID:SCR_004380)

Description: Aims to carry out an integrated (epi)genomic analysis of the NET BioBank established at the Royal Free and UCL Hospitals to identify new biomarkers for translation into diagnostics and therapeutics. The Neuroendocrine Tumour (NET) Unit at the Royal Free Campus of UCL Hospitals has an international reputation for the management of neuroendocrine tumor patients. It currently receives around 10 new referrals per month and has an active patient cohort of over 800 patients. We receive referrals from across the UK as well as from abroad. It is the designated center for NETs within the North London Cancer Network. In order to improve both treatment and outcome in Neuroendocrine Tumors (NETs), better understanding of their biology and the biological pathways involved is imperative (reviewed in (Modlin et al., 2008)). Currently, the use of targeted treatments is limited and management challenging due to the lack of knowledge of the molecular pathogenesis and mechanistic regulation of these tumors (Barakat et al., 2004). Due to the rarity of NETs and difficulty in obtaining fresh tissue and archival samples, very little is known about the (epi)genetic and germline mutations associated with neuroendocrine tumors ?????? which encompass a clinically and genetically heterogeneous group. To date, studies have been small and under-powered. Clinical trials have included small patient numbers and are often non-randomized phase II trials comparing a new therapy against a non-standardized first line treatment. Initially we will undertake genome-wide methylation analysis on our entire cohort of neuroendocrine tumors in order to determine the methylation profiles of differing NET types. This will improve diagnostic accuracy and potentially identify new therapeutic targets and biomarkers. These studies will be performed on high-throughput analysis platforms based on microarrays and next-generation sequencing. In parallel, we will analyze the mRNA expression profiles of these tumors to enable integrated (epi)genomic analysis of these intriguing tumors.

Abbreviations: NET BioBank

Resource Type: biomaterial supply resource, material resource, tissue bank

Keywords: tissue, tumor, neuroendocrine tumor, cancer, epigenomics

Related Condition: Neuroendocrine tumor

Funding: Cancer Research UK

Availability: Potentially for national and international collaboration with the aim of improving the quality and quantity of research into NETs in both the clinical and basic science settings.

Resource Name: Neuroendocrine Tumors Biobank

Resource ID: SCR_004380

Alternate IDs: nlx_39248

Old URLs: http://www.ucl.ac.uk/cancer/research-groups/medical-genomics/NET_BioBank/index.htm

Record Creation Time: 20220129T080224+0000

Record Last Update: 20260905T133124+0000

Ratings and Alerts

No rating or validation information has been found for Neuroendocrine Tumors Biobank.

No alerts have been found for Neuroendocrine Tumors Biobank.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We have not found any literature mentions for this resource.